Renaissance Technologies LLC Raises Stock Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Renaissance Technologies LLC increased its stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 131.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 193,100 shares of the company's stock after acquiring an additional 109,700 shares during the quarter. Renaissance Technologies LLC owned approximately 0.74% of Eton Pharmaceuticals worth $2,572,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently modified their holdings of ETON. Jane Street Group LLC bought a new position in Eton Pharmaceuticals in the third quarter worth about $90,000. Raymond James Financial Inc. bought a new position in shares of Eton Pharmaceuticals in the 4th quarter worth approximately $147,000. Hillsdale Investment Management Inc. purchased a new position in shares of Eton Pharmaceuticals in the 4th quarter valued at approximately $226,000. Envestnet Asset Management Inc. bought a new stake in shares of Eton Pharmaceuticals during the fourth quarter valued at approximately $236,000. Finally, Baader Bank Aktiengesellschaft purchased a new stake in Eton Pharmaceuticals in the fourth quarter worth $373,000. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on ETON shares. B. Riley reiterated a "buy" rating and set a $24.00 target price (up from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th. HC Wainwright reissued a "buy" rating and issued a $33.00 target price on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th. Finally, Craig Hallum upped their price target on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a "buy" rating in a research report on Wednesday, March 19th.

Eton Pharmaceuticals Trading Up 2.2 %

NASDAQ ETON traded up $0.36 on Wednesday, hitting $16.85. 197,274 shares of the company traded hands, compared to its average volume of 179,367. The company has a market capitalization of $451.88 million, a price-to-earnings ratio of -76.59 and a beta of 1.34. Eton Pharmaceuticals, Inc. has a 52-week low of $3.18 and a 52-week high of $18.41. The business's 50 day moving average price is $14.16 and its 200-day moving average price is $13.13.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, hitting analysts' consensus estimates of ($0.02). The company had revenue of $11.65 million for the quarter, compared to analysts' expectations of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. As a group, sell-side analysts predict that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.